Business Overview: Co-Diagnostics, Inc. (Nasdaq: CODX)

Executive Summary

Co-Diagnostics is a molecular diagnostics company built around a proprietary PCR primer chemistry — Co-Primers® — that the company says materially reduces false-positive results in DNA/RNA amplification testing relative to conventional primer designs used by most competitors. The technology is protected by more than 20 granted or pending patents and underpins the company's Logix Smart® line of laboratory-based PCR tests (covering COVID-19, influenza, tuberculosis, hepatitis, HPV, and other infectious diseases) as well as Vector Smart® mosquito-surveillance products. Co-Diagnostics rose to prominence during the COVID-19 pandemic on the strength of its CE-marked and FDA-EUA-authorized COVID-19 test, but has since had to rebuild its business around a broader, post-pandemic infectious-disease testing menu and a new point-of-care ambition: the Co-Dx™ PCR Pro platform, a portable device currently under FDA review for multiplex flu A/B, COVID-19, and RSV testing.

The single most decision-relevant fact right now is that Co-Diagnostics remains a cash-burning, sub-scale diagnostics company in the difficult post-pandemic reset that has hit most COVID-era testing companies: as of fiscal year-end 2025 the company reported just $11.9 million of cash against an accumulated deficit of $80.4 million, meaning its runway and its ability to commercialize the Co-Dx PCR Pro point-of-care platform are the central questions for the stock. The company's manufacturing is partly de-risked through its 50%-owned CoSara joint venture in India and a newly formed CoMira venture targeting Saudi Arabia/MENA, which lower capital intensity and provide access to lower-cost, high-volume manufacturing and emerging-market distribution, but the core challenge remains converting patented chemistry into durable, profitable commercial volume against much larger, better-capitalized diagnostics incumbents.

Co-Diagnostics should be viewed as a technology-differentiated but financially fragile small-cap diagnostics company: the Co-Primers IP is real and defensible, but the business has not yet proven it can generate sustainable revenue and profitability at a scale that justifies its cost structure absent another infectious-disease demand shock.

1. Core Business Model & How They Work

Co-Diagnostics generates revenue by developing, manufacturing, and selling PCR-based diagnostic test kits and reagents, plus (pending FDA clearance) point-of-care hardware:

1. Sell Logix Smart® laboratory PCR test kits for infectious diseases (COVID-19, influenza, tuberculosis, hepatitis, HPV, and others) to laboratories and healthcare systems globally.
2. License and leverage proprietary Co-Primers® chemistry, which the company states avoids the royalty payments that competitors using licensed primer technology must pay, supporting relatively favorable gross margins on a smaller revenue base.
3. Manufacture through joint-venture partnerships — CoSara (50%-owned, India) provides lower-cost manufacturing capacity, while the newly formed CoMira venture targets Saudi Arabia/MENA production and distribution.
4. Distribute globally through networks spanning more than 50 countries across Europe, Asia, the Americas, and the Middle East.
5. Pursue regulatory clearance for the Co-Dx™ PCR Pro platform, a portable point-of-care multiplex device (flu A/B, COVID-19, RSV) currently under FDA review — the company's principal near-term catalyst for diversifying beyond laboratory-only testing.
6. Sell Vector Smart® mosquito-surveillance tests to public-health and vector-control customers, diversifying beyond human diagnostics.

2. Business Segments

Co-Diagnostics operates as a single diagnostics business rather than multiple reported segments, with revenue derived across its Logix Smart human-diagnostics line, Vector Smart surveillance products, and (prospectively) the Co-Dx PCR Pro point-of-care platform once cleared.

3. Product Portfolio

4. Competitive Landscape

Co-Diagnostics competes against far larger, better-resourced molecular diagnostics companies. Roche Diagnostics, Abbott Laboratories, QIAGEN, and Cepheid (Danaher) dominate the global PCR and molecular testing market with broad menus, established lab relationships, and significant commercial infrastructure. Co-Diagnostics' pitch to customers rests on affordability, faster test-design cycle times, accuracy claims tied to its Co-Primers chemistry, and full ownership of its core IP (avoiding royalty costs that the company argues some competitors bear). In the emerging point-of-care segment, the Co-Dx PCR Pro platform, once cleared, would compete against established point-of-care molecular platforms such as Cepheid's GeneXpert and Abbott's ID NOW.

Key Competitors:

• Roche Diagnostics (global PCR/molecular testing leader)
• Abbott Laboratories (ID NOW and broad diagnostics portfolio)
• QIAGEN (PCR reagents and molecular diagnostics)
• Cepheid / Danaher (GeneXpert point-of-care molecular platform)
• Thermo Fisher Scientific (PCR reagents and diagnostics)

5. Strategic Strengths & Risks

Competitive Strengths (The Moat)

• Proprietary Co-Primers® chemistry, protected by more than 20 granted/pending patents, provides genuine technical differentiation on false-positive reduction.
• Full ownership of core primer IP avoids royalty payments that burden some competitors, supporting relatively favorable unit economics on a small base.
• Joint-venture manufacturing (CoSara in India, CoMira in MENA) provides lower-cost production and localized market access without full capital investment.
• Established global distribution footprint across 50+ countries built up during the pandemic.

Strategic Risks & Vulnerabilities

1. Severe post-pandemic revenue reset — like most COVID-era diagnostics companies, Co-Diagnostics has had to rebuild demand around a smaller, more competitive endemic-disease testing market.
2. Thin cash position relative to accumulated losses — $11.9 million of cash against an $80.4 million accumulated deficit signals a limited runway absent new financing, revenue inflection, or cost cuts.
3. Regulatory dependency — the Co-Dx PCR Pro point-of-care growth catalyst remains under FDA review with no guaranteed clearance timeline or outcome.
4. Scale disadvantage — Roche, Abbott, QIAGEN, and Danaher each dwarf Co-Diagnostics in R&D budget, sales infrastructure, and menu breadth.
5. Joint-venture dependency — reliance on CoSara and CoMira for manufacturing introduces partner and geopolitical/regulatory risk in India and the Middle East.

6. Financial Overview

7. Summary Conclusion

Co-Diagnostics owns a real, patent-protected technical advantage in PCR primer chemistry, and its Co-Primers platform genuinely differentiates its test kits on false-positive performance and royalty-free economics. However, the company remains financially fragile in the post-pandemic diagnostics reset, with a limited cash position relative to its accumulated losses and its next major growth catalyst — FDA clearance and commercialization of the Co-Dx PCR Pro point-of-care platform — still pending and unproven. The investment case is best framed as a call option on successful point-of-care commercialization and continued endemic-disease testing demand, tempered by real going-concern-adjacent liquidity risk if clearance is delayed or underlying test-kit revenue does not stabilize.